A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
A Multicenter, Randomized, Blinded, Placebo-Controlled Confirmatory Clinical Trial of Autologous REGEND001 Cell Therapy for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function, impaired quality of life, and a significant healthcare burden. REGEND001, made from airway basal stem cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, blinded, placebo-parallel-controlled trial is performed to verify the efficacy and safety of REGEND001 in treatment of COPD patients with emphysema.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Shiyue Li, Professor and Chief Physician
- 電話番号:86-20-83062114
- メール:lishiyue@188.com
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国
- The First Affiliated Hospital of Guangzhou Medical University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female, aged 40-75 years;
- Diagnosed with COPD;
- Post-bronchodilator FEV1/FVC <0.7
- Emphysematous lesions demonstrated by HRCT;
- Hemoglobin-corrected DLCO%predicted ≥20% and <70%;
- Post-bronchodilator FEV1%predicted ≤80%;
- COPD Assessment Test (CAT) score ≥3;
Exclusion Criteria:
- History of ≥2 COPD exacerbations leading to hospitalization within 1 year prior to screening, or a COPD exacerbation leading to hospitalization within 2 months prior to screening;
- Current or previous history of malignancy;
- An assessed life expectancy of <1 year;
- Respiratory tract infection or systemic infection requiring treatment, or severe localized infection within 4 weeks prior to screening;
- History of invasive or non-invasive mechanical ventilation within 4 weeks prior to screening;
- Diagnosis of pneumonia within 3 months prior to screening;
- Abnormal coagulation function affecting the safety of fiberoptic bronchoscopy procedures at screening;
- Subjects requiring long-term maintenance anticoagulant therapy or antiplatelet therapy, who are unable to discontinue such medications for at least 1 week prior to cell collection and cell infusion;
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Participants randomized to the Placebo Comparator arm will receive a single administration of placebo. |
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of placebo via bronchoscopy and 1 year of follow-up. |
|
実験的:REGEND001
Participants randomized to the experimental arm will receive a single administration of REGEND001. |
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of REGEND001 via bronchoscopy and 1 year of follow-up. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in the measured Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
時間枠:Week 52 after treatment
|
The change from baseline in measured DLCO is defined as the difference between the absolute measured DLCO value at baseline and that measured at the assessment time point after treatment. |
Week 52 after treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in COPD Assessment Test (CAT) score
時間枠:Week 12, 24 and 52 after treatment
|
The COPD Assessment Test (CAT) is an 8-item questionnaire used to assess the impact of COPD on health status. The total score ranges from 0 to 40, with higher scores indicating a greater impact of COPD and worse health status. Change from baseline is calculated as the post-treatment CAT score minus the baseline CAT score. |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥2-point improvement or worsening from baseline in CAT score
時間枠:Week 12, 24 and 52 after treatment
|
Minimal clinically important difference for CAT is recognized as 2 points. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in DLCO
時間枠:Week 12, 24 and 52 after treatment
|
DLCO is assessed by absolute measured value, hemoglobin (Hb)-corrected measured/predicted ratios and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥11% relative improvement or worsening from baseline in absolute measured DLCO
時間枠:Week 12, 24 and 52 after treatment
|
Minimal clinically important difference (MCID) of DLCO is recognized as 11%. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in alveolar volume (VA)
時間枠:Week 12, 24 and 52 after treatment
|
VA is assessed by measured values, measured/predicted ratio and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in forced expiratory volume in the first second (FEV1) post-bronchodilator
時間枠:Week 12, 24 and 52 after treatment
|
FEV1 is assessed by measured value, measured/predicted ratio and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in 6-minute walk distance (6MWD)
時間枠:Week 12, 24 and 52 after treatment
|
6MWD is assessed by the measured value and corresponding area under curve |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥30-meter change from baseline in 6MWD
時間枠:Week 12, 24 and 52 after treatment
|
Minimal clinically important difference (MCID) of 6MWD is recognized as 30 meters. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in St. George's Respiratory Questionnaire for COPD (SGRQ-C) score
時間枠:Week 12, 24 and 52 after treatment
|
The St. George's Respiratory Questionnaire for COPD (SGRQ-C) is a validated disease-specific patient-reported outcome measure used to assess the impact of COPD on patients' health status and quality of life. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome. |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥4-point improvement or worsening from baseline in SGRQ-C score
時間枠:Week 12, 24 and 52 after treatment
|
Minimal clinically important difference for SGRQ is recognized as 4 points. |
Week 12, 24 and 52 after treatment
|
|
Annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics
時間枠:Week 52 after treatment
|
The annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics, represents the adjusted frequency of acute exacerbations of COPD over the assessment period. |
Week 52 after treatment
|
|
Change from baseline in arterial blood gas parameters
時間枠:Week 52 after treatment
|
The change from baseline in arterial blood gas parameters reflects changes in gas exchange function and respiratory status over the assessment period. |
Week 52 after treatment
|
|
Change from baseline in HRCT images
時間枠:Week 52 after treatment
|
HRCT images are quantitatively analyzed using dedicated software to measure emphysema volume (mL) and functional lung volume (mL). |
Week 52 after treatment
|
|
Adverse Event
時間枠:Hour 24, Week 12, 24 and 52 after treatment
|
An adverse event (AE) is any untoward medical occurrence in a subject who has received a study intervention, regardless of whether or not it is considered related to the intervention. |
Hour 24, Week 12, 24 and 52 after treatment
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- REGEND001-COPD-251
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。